Fiche société
Royal Brompton & Harefield NHS Foundation Trust
Traitements, essais et publications liés.
Traitements2programmes
Essais2liés
Publications3liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| HydrocortisoneThe purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as assessed by Blinded Independent Central Review (BICR), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants. | Cancer, SEP | À vérifier | Ralentissement de la progression | United Kingdom | À vérifier |
| HydrocortisoneThe purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as assessed by Blinded Independent Central Review (BICR), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants. | Cancer | Phase 2 | Ralentissement de la progression | United States | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Aminophylline | SEP | À vérifier | NCT02270827 | SARAH — A Pilot Study Into Health Pre and Post Treatment With Intravenous Aminophylline and Hydrocortisone in Severe Asthmatics | TERMINATED |
| Hydrocortisone | Cancer | Phase 2 | NCT07763210 | Lazarus: IT Therapy for ICANS | NOT_YET_RECRUITING |
Publications
3| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Hydrocortisone | Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults. | Stress (Amsterdam, Netherlands) | ||
| Hydrocortisone | The impact of (poly)phenol-rich sugarcane extract intervention on markers of gastrointestinal integrity and systemic inflammation in response to exertional-heat stress. | Journal of the International Society of Sports Nutrition | ||
| Hydrocortisone | The association between pubertal timing and diurnal cortisol activity in middle adolescence. | Stress (Amsterdam, Netherlands) |